Evaluation of tocilizumab therapy in patients with rheumatoid arthritis based on FDG-PET/CT

BMC Musculoskeletal Disorders

Kenji Takagishi¹  Yoshito Tsushima²  Tetsuya Higuchi²  Chisa Okura¹  Yukio Yonemoto¹  Koichi Okamura¹ 

[1] Department of Orthopaedic Surgery, Gunma University Graduate School of Medicine, 3-39-22, Showamachi, Maebashi, Gunma 371-8511, Japan;Department of Diagnostic Radiology and Nuclear Medicine, Gunma University Graduate School of Medicine, Maebashi, Gunma, Japan

关键词: Tocilizumab;    Synovitis;    SUV;    Positron emission tomography;    Interleukin-6;    Rheumatoid arthritis;   

Others  :  1091570
DOI  :  10.1186/1471-2474-15-393

 received in 2014-10-25, accepted in 2014-11-07,  发布年份 2014

【 摘 要 】

Background

Positron emission tomography (PET) with 2-[18F]-fluoro-2-deoxy-D-glucose (¹⁸F-FDG) can detect the presence of synovitis in rheumatoid arthritis (RA) patients. The aim of this study was to investigate whether the findings of FDG-PET matched the conventional assessments of the disease activity score (DAS) 28, DAS28-CRP, simplified disease activity index (SDAI) and clinical disease activity index (CDAI) in RA patients receiving tocilizumab (TCZ) therapy.

Methods

Seventeen RA patients treated with TCZ were assessed. FDG-PET was performed at baseline and three and six months after the initiation of TCZ therapy. The maximum SUV (SUVmax) of the bilateral shoulder, elbow, wrist, hip, knee and ankle joints were added together (total SUV) and were used to assess the degree of FDG uptake as a representative parameter. The correlations between the ΔSUV and the difference in the clinical parameters at baseline and at each observation period, and the differences in each clinical parameters, were assessed.

Results

The ΔSUV, the differences in the total SUV at baseline and at three/six months after starting treatment positively correlated with the ΔDAS28 (r = 0.615 p = 0.009/ r = 0.775 p < 0.001), ΔDAS28-CRP (r = 0.696, p = 0.002/ r = 0.828, p < 0.001), ΔSDAI (r = 0.652, p = 0.005/ r = 0.686, p = 0.002) and ΔCDAI (r = 0.662, p = 0.004/ r = 0.711, p = 0.001) for each period. The total SUV was significantly decreased at three and six months after the initiation of TCZ (p < 0.05).

Conclusions

A reduction in the FDG uptake was observed at three and six months after the initiation of TCZ therapy. The disease activity estimated on FDG-PET/CT matched the conventional parameters following the TCZ therapy in RA patients.

【 授权许可】

   
2014 Okamura et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

【 参考文献 】

• [1]Kiely PD, Deighton C, Dixey J, Ostör AJ: Biologic agents for rheumatoid arthritis–negotiating the NICE technology appraisals. Rheumatology (Oxford) 2012, 51:24-31.
• [2]Ogata A, Hirano T, Hishitani Y, Tanaka T: Safety and efficacy of tocilizumab for the treatment of rheumatoid arthritis. Clin Med Insights Arthritis Musculoskelet Disord 2012, 5:27-42.
• [3]Nishimoto N, Kishimoto T: Humanized antihuman IL-6 receptor antibody, tocilizumab. Handb Exp Pharmacol 2008, 181:151-160.
• [4]Nishimoto N, Yoshizaki K, Maeda K, Kuritani T, Deguchi H, Sato B, Imai N, Suemura M, Kakehi T, Takagi N, Kishimoto T: Toxicity, pharmacokinetics, and dose-finding study of repetitive treatment with the humanized anti-interleukin 6 receptor antibody MRA in rheumatoid arthritis. Phase I/II clinical study. J Rheumatol 2003, 30:1426-1435.
• [5]Funahashi K, Koyano S, Miura T, Hagiwara T, Okuda K, Matsubara T: Efficacy of tocilizumab and evaluation of clinical remission as determined by CDAI and MMP-3 level. Mod Rheumatol 2009, 19:507-512.
• [6]Kaneko A, Kida D, Saito K, Tsukamoto M, Sato T: Clinical results for tocilizumab over one year in the clinical setting as assessed by CDAI (clinical disease activity index): CRP at week 12 and MMP-3 at week 24 are predictive factors for CDAI. Rheumatol Int 2012, 32:3631-3637.
• [7]Mierau M, Schoels M, Gonda G, Fuchs J, Aletaha D, Smolen JS: Assessing remission in clinical practice. Rheumatology (Oxford) 2007, 46:975-979.
• [8]Smolen JS, Landewé R, Breedveld FC, Buch M, Burmester G, Dougados M, Emery P, Gaujoux-Viala C, Gossec L, Nam J, Ramiro S, Winthrop K, de Wit M, Aletaha D, Betteridge N, Bijlsma JW, Boers M, Buttgereit F, Combe B, Cutolo M, Damjanov N, Hazes JM, Kouloumas M, Kvien TK, Mariette X, Pavelka K, van Riel PL, Rubbert-Roth A, Scholte-Voshaar M, Scott DL, et al.: EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update. Ann Rheum Dis 2014, 73:492-509.
• [9]Wang SC, Xie Q, Lv WF: Positron emission tomography/computed tomography imaging and rheumatoid arthritis. Int J Rheum Dis 2014, 17:248-255.
• [10]McQueen FM, Ostergaard M: Established rheumatoid arthritis - new imaging modalities. Best Pract Res Clin Rheumatol 2007, 21:841-856.
• [11]Beckers C, Jeukens X, Ribbens C, André B, Marcelis S, Leclercq P, Kaiser MJ, Foidart J, Hustinx R, Malaise MG: (18)F-FDG PET imaging of rheumatoid knee synovitis correlates with dynamic magnetic resonance and sonographic assessments as well as with the serum level of metalloproteinase-3. Eur J Nucl Med Mol Imaging 2006, 33:275-280.
• [12]Palmer WE, Rosenthal DI, Schoenberg OI, Fischman AJ, Simon LS, Rubin RH, Polisson RP: Quantification of inflammation in the wrist with gadolinium-enhanced MR imaging and PET with 2-[F-18]-fluoro-2-deoxy-D-glucose. Radiology 1995, 196:647-655.
• [13]Polisson RP, Schoenberg OI, Fischman A, Rubin R, Simon LS, Rosenthal D, Palmer WE: Use of magnetic resonance imaging and positron emission tomography in the assessment of synovial volume and glucose metabolism in patients with rheumatoid arthritis. Arthritis Rheum 1995, 38:819-825.
• [14]Goerres GW, Forster A, Uebelhart D, Seifert B, Treyer V, Michel B, von Schulthess GK, Kaim AH: F-18 FDG whole-body PET for the assessment of disease activity in patients with rheumatoid arthritis. Clin Nucl Med 2006, 31:386-390.
• [15]Vijayant V, Sarma M, Aurangabadkar H, Bichile L, Basu S: Potential of (18)F-FDG-PET as a valuable adjunct to clinical and response assessment in rheumatoid arthritis and seronegative spondyloarthropathies. World J Radiol 2012, 4:462-468.
• [16]Roivainen A, Hautaniemi S, Möttönen T, Nuutila P, Oikonen V, Parkkola R, Pricop L, Ress R, Seneca N, Seppänen M, Yli-Kerttula T: Correlation of 18F-FDG PET/CT assessments with disease activity and markers of inflammation in patients with early rheumatoid arthritis following the initiation of combination therapy with triple oral antirheumatic drugs. Eur J Nucl Med Mol Imaging 2013, 40:403-410.
• [17]Beckers C, Ribbens C, André B, Marcelis S, Kaye O, Mathy L, Kaiser MJ, Hustinx R, Foidart J, Malaise MG: Assessment of disease activity in rheumatoid arthritis with (18)F-FDG PET. J Null Med 2004, 45:956-964.
• [18]Okamura K, Yonemoto Y, Arisaka Y, Takeuchi K, Kobayashi T, Oriuchi N, Tsushima Y, Takagishi K: The assessment of biologic treatment in patients with rheumatoid arthritis using FDG-PET/CT. Rheumatology (Oxford) 2012, 51:1484-1491.
• [19]Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, Healey LA, Kaplan SR, Liang MH, Luthra HS, Medsger TA Jr, Mitchell DM, Neustadt DH, Pinals RS, Schaller PJ, Sharp JT, Wilder RL, Hunder GG: The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988, 31:315-324.
• [20]DAS SCORE.NL the Netherlands; http://www.das-score.nl/ webcite
• [21]Smolen JS, Breedveld FC, Schiff MH, Kalden JR, Emery P, Eberl G, van Riel PL, Tugwell P: A simplified disease activity index for rheumatoid arthritis for use in clinical practice. Rheumatology (Oxford) 2003, 42:244-257.
• [22]Aletaha D, Smolen J: The Simplified Disease Activity Index (SDAI) and the Clinical Disease Activity Index (CDAI): A review of their usefulness and validity in rheumatoid arthritis. Clin Exp Rheumatol 2005, 23:S100-S108.
• [23]Curtin F, Schulz P: Multiple correlations and Bonferroni’s correction. Biol Psychiatry 1998, 44:775-777.
• [24]Mihara M, Moriya Y, Kishimoto T, Ohsugi Y: Interleukin-6 (IL-6) induces the proliferation of synovial fibroblastic cells in the presence of soluble IL-6 receptor. Br J Rheumatol 1995, 34:321-325.
• [25]Mihara M, Moriya Y, Kishimoto T, Ohsugi Y: Treatment of rheumatoid synovitis with anti-reshaping human interleukin-6 receptor monoclonal antibody. Arthritis Rheum 1998, 41:2014-2021.
• [26]Hashizume M, Hayakawa N, Suzuki M, Mihara M: IL-6/sIL-6R trans-signalling, but not TNF-alpha induced angiogenesis in a HUVEC and synovial cell co-culture system. Rheumatol Int 2009, 29:1449-1454.
• [27]Suzuki M, Hashizume M, Yoshida H, Mihara M: Anti-inflammatory mechanism of tocilizumab, a humanized anti-IL-6R antibody: effect on the expression of chemokine and adhesion molecule. Rheumatol Int 2010, 30:309-315.
• [28]Nakatani A, Takahashi M, Momose T, Ohtomo K, Koyasu S: Inflammatory cytokines and hypoxia contribute to 18F-FDG uptake by cells involved in pannus formation in rheumatoid arthritis. J Nucl Med 2009, 50:920-926.
• [29]Kamishima T, Tanimura K, Shimizu M, Matsuhashi M, Fukae J, Kon Y, Hagiwara H, Narita A, Aoki Y, Kosaka N, Atsumi T, Shirato H, Terae S: Monitoring anti-interleukin 6 receptor antibody treatment for rheumatoid arthritis by quantitative magnetic resonance imaging of the hand and power Doppler ultrasonography of the finger. Skeletal Radiol 2011, 40:745-755.
• [30]Suzuki T, Horikoshi M, Sugihara M, Hirota T, Ogishima H, Umeda N, Kondo Y, Tsuboi H, Hayashi T, Chino Y, Matsumoto I, Sumida T: Therapeutic efficacy of tocilizumab in patients with rheumatoid arthritis refractory to anti-tumor-necrosis-factor inhibitors: 1 year follow-up with low-field extremity MRI. Mod Rheumatol 2013, 23:782-787.